January 19, 2017 – Opdivo (nivolumab) Demonstrated Efficacy and Improved Survival in Patients with Previously Treated Advanced Gastric Cancer in a Randomized Phase 3 Study

In a press release, Bristol-Myers Squibb announced the results of their phase 3 randomized clinical trial (ONO-4538-12) conducted in Japan, Korea and Taiwan to assess the safety and efficacy of Opdivo (nivolumab) in patients with unresectable, previously-treated advanced or recurrent gastric and gastroesophageal cancer. The 12-month overall survival (OS) was 26.6% in the patients who were treated with Opdivo compared with 10.9% in the patients treated with the placebo, and the objective response rate in the Opdivo-treated group was 11.2% with a median response duration of 9.53 months, compared to 0% response in the placebo group. The Opdivo-treated patients and the patients given the placebo also had similar rates of treatment-related adverse events. These results are being presented at the 2017 Gastrointestinal Cancers Symposium in San Francisco, California.
Molecular Testing
View Full Article
Related Videos

Leave a Comment